Sean is a member of the firm’s Capital Markets Group. Working with clients across a variety of industries, his practice focuses on securities law, corporate finance, and mergers and acquisitions. Sean also assists clients in meeting ongoing disclosure requirements.
When it comes to complex capital markets transactions, Sean provides clients with the support they need to navigate regulatory requirements and achieve their business goals. He is highly organized in his approach and delivers concise advice that his clients can trust.
Represented Cybin Inc. (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, in the completion of an overnight marketed offering pursuant to a prospectus supplement to Cybin’s short form base shelf prospectus, with aggregate gross proceeds of approximately $34 million.
Represented Small Pharma Ltd, a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, in its acquisition by Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) by way of a qualifying transaction and its related brokered and non-brokered private placements for aggregate gross proceeds of $63 million and initial TSX Venture Exchange listing.
Represented Cybin Inc. in the completion of its reverse takeover of Clarmin Explorations Inc. pursuant to the terms of an amalgamation agreement among Cybin Corp., Clarmin and a wholly-owned subsidiary of the Company as well as a private placement offering of 60 million subscription receipts for aggregate gross proceeds of $45 million.